75.13 USD
↗ 1.31 (1.78%)AT CLOSE (11:59 AM EDT)
Ionis Pharmaceuticals, Inc. Common Stock
IONSNASDAQ • USD
74.00
↘ 1.13 (1.50%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
74.00
↘ 1.13 (1.50%)
Market: CLOSED
Open?$74.01
High?$75.88
Low?$73.82
Prev. Close?$73.82
Volume?1.2M
Avg. Volume?1.8M
VWAP?$75.21
Rel. Volume?0.69x
Bid / Ask
Bid?$70.91 × 100
Ask?$79.01 × 100
Spread?$8.10
Midpoint?$74.96
Valuation & Ratios
Market Cap?12.2B
Shares Out?165.3M
Float?157.0M
Float %?95.1%
P/E Ratio?N/A
P/B Ratio?24.83
EPS?-$1.98
Dividend?0.00%
Ex-Dividend?N/A
IONS is currently priced at $75.12. Technicals currently rate "Neutral" while our fundamental analysis reads "Neutral". This is driven by negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, IONS trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jun 4, 2026.
News
Profile
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Themes
Address
2855 GAZELLE COURT
CARLSBAD, CA 92010
Phone: (760) 931-9200
CARLSBAD, CA 92010
Phone: (760) 931-9200
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?32
Momentum?62
Short Sent.?48
Piotroski F-Score?3/9Weak
Altman Z-Score?1.89Grey
Confidence?74%Moderate
Short InterestVery High
Short % of Float?10.24%High
Short Interest?16.1M
Days to Cover?10.0
Free Float157.0M
Avg Daily Volume1.6M
Settlement Date2026-05-15
Financial Health
Current Ratio?3.22Strong
Quick Ratio?3.21Strong
Cash Ratio?0.24Low
Debt/Equity?3.57High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score50/100
P/E?N/A▾
P/B?24.83HIGH▾
Peers100
S&P3
P/S?11.53HIGH▾
Peers100
S&P6
P/FCF?N/A▾
EV/EBITDA?-40.4CHEAP▾
S&P97
EV/Sales?13.02HIGH▾
Peers100
S&P6
Returns & Efficiency
ROE?-66.5%WEAK▾
S&P3
ROA?-9.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-971257000
Enterprise Value?$13.8B
Fundamentals ratios updated end of day